Related Experiment Video
Updated: May 16, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Circulating Tumor DNA Dynamic Changes in Esophageal Squamous Cell Carcinoma Receiving Immunochemotherapy
Yijia Guo1, Wang Qu1, Yun Liu1
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background:
Immune checkpoint inhibitors have revolutionized the treatment strategy of esophageal squamous cell carcinoma (ESCC). The value of ctDNA dynamic changes in ESCC patients treated with immunochemotherapy was not clear.
Methods:
A retrospective analysis was performed to analyze the association of ctDNA dynamic changes with the treatment efficacy of immunochemotherapy in patients with locally advanced, metastatic, or recurrent ESCC and who received immunochemotherapy at the Department of Medical Oncology, National Cancer Center from June 2023 to December 2024. Tumor mutation burden (TMB) and PD-L1 expression of tumor tissue were also explored.
Results:
57 patients with paired ctDNA at baseline and during treatment were analyzed. We found that patients with negative ctDNA during treatment demonstrated a higher tumor regression rate (96.8% vs. 73.1%; p = 0.018) and a higher cCR rate (45.2% vs. 15.4%; p = 0.022). Additionally, patients with continuously negative ctDNA (p = 0.033) or experienced ctDNA clearance during treatment (p = 0.043) had a higher cCR rate compared to those with persistently positive ctDNA. Moreover, among patients with TP53 mutations at baseline, those with TP53 mutations cleared during treatment showed a higher tumor regression rate (88.9% vs. 54.5%; p = 0.031) and cCR rate (33.3% vs. 0%; p = 0.038) compared to patients with persistent TP53 mutations. No correlation was observed between TMB and treatment efficacy, while a higher cCR rate was observed in patients with PD-L1 CPS ≥ 15 (63.6% vs. 24.4%; p = 0.027).
Conclusions:
ctDNA dynamic changes demonstrated potential predictive value for the efficacy of immunochemotherapy in patients with ESCC. Further exploration through larger-scale studies is necessary.
